Nordic Life Science 1
A C Q UI S I T ION Investor AB has undertaken to
accept the September 2 public offer made by Agnafit Bidco for the shares in Swedish Orphan Biovitrum at a price per share of SEK 235. T HE BID, VALUING the rare disease drugmaker at about 69.4 billion SEK was made by Advent International Corporation and Aurora Investment Pte Ltd, an affiliate of GIC Pte Ltd, through Agnafit Bidco AB. Investor was instrumental in the creation of Sobi in 2010 as the lead shareholder of its predecessors Swedish Orphan International and Biovitrum. “We believe that the offer is financially attractive. Assuming completion of the offer, Investor’s financial position will be further strengthened. We intend to utilize this strength by continuing to invest in existing and new platform companies within Patricia Industries, selectively invest within Listed Companies as well as in EQT funds,” says Investor’s President and CEO Johan Forssell. Assuming that the offer is declared unconditional, the transaction is expected to complete in the fourth quarter of 2021. This the one of the largest buyouts of a Nordic company in more than five years. Guido Oelkers, CEO, Sobi PHOTO MARTIN BOTVIDSSON